Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensified NYI Regimen for Newly-Diagnosed Disseminated Anaplastic Large Cell Ki-1 Lymphoma and T-Large Cell Lymphoma
NCT00002590Phase 2Completed
- Sponsor
- Children's Oncology Group
- Start
- Jul 1994
- Primary completion
- Mar 2001
- Modality
- DNA Intercalators/Alkylators, Therapeutic Enzymes, Orthosteric Ligands
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide, cytarabine, daunorubicin, doxorubicin, etoposide and 7 more in anaplastic large cell lymphoma (ALCL) and T-cell large cell lymphoma, sponsored by Children's Oncology Group. Primary endpoint: Toxicity and feasibility of 11 month multiagent chemotherapy. Started Jul 1994; status: completed.
02
Drugs
cyclophosphamidecytarabinedaunorubicindoxorubicinetoposide
03
Conditions
anaplastic large cell lymphoma (ALCL)T-cell large cell lymphoma
Beyond the preview
Go deeper on NCT00002590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002590.